Hemostatic Tissue Sealants

Hemostatic Tissue Sealants Market Outlook

The global hemostatic tissue sealants market is poised for significant expansion, projected to reach approximately USD 5.1 billion by 2035, growing at a CAGR of around 6.8% during the forecast period from 2025 to 2035. The increasing incidence of surgical procedures, along with the rising emphasis on minimally invasive surgeries and advancements in surgical techniques, is fueling the market's growth. Additionally, growing awareness regarding the benefits of hemostatic agents in improving surgical outcomes and minimizing blood loss is further driving demand. As healthcare systems evolve and the need for effective hemostatic solutions rises, the market is expected to witness substantial investments in research and development, ultimately enhancing the range of available products. This market outlook reflects not only the financial potential but also the broadening applications of hemostatic sealants across various surgical disciplines.

Growth Factor of the Market

Several factors are contributing to the growth of the hemostatic tissue sealants market. The increasing number of surgical procedures undertaken globally is one of the primary drivers; as the global population grows and ages, the demand for surgical interventions rises across various specialties including orthopedic, cardiovascular, and neurosurgery. Additionally, advancements in technology have led to the development of innovative hemostatic products that are more effective and user-friendly, thus encouraging their adoption by healthcare professionals. The rising incidence of trauma cases, which often require rapid hemostatic solutions, is another significant factor propelling market growth. Furthermore, increasing investments in healthcare infrastructure and the growing trend of outpatient surgeries are further augmenting the market's trajectory. The emphasis on patient safety and the reduction of post-operative complications associated with traditional methods for managing bleeding is also boosting the demand for hemostatic tissue sealants.

Key Highlights of the Market

• Significant growth in the hemostatic tissue sealants market projected at a CAGR of 6.8% from 2025 to 2035.
• Rising demand for minimally invasive surgical procedures enhancing market adoption of hemostatic agents.
• Technological advancements leading to the development of innovative hemostatic products.
• Increasing focus on improving patient outcomes and reducing surgical complications driving market growth.
• Expanding applications in various surgical specialties, including general, cardiac, vascular, and orthopedic surgeries.

By Product Type

Collagen-based Hemostatic Sealants:

Collagen-based hemostatic sealants are derived from natural collagen sources and are widely used in surgical procedures due to their biocompatibility and effectiveness in promoting clot formation. These sealants facilitate wound healing by triggering the body’s natural coagulation cascade, which enhances the body's response to surgical trauma. Their application is particularly prevalent in surgeries where rapid hemostasis is critical. The growing body of clinical evidence demonstrating the efficacy of collagen-based sealants in various surgical settings is expected to bolster their demand further. Furthermore, the ease of use and versatility of these products make them a preferred choice among surgeons, contributing to their significant market share.

Gelatin-based Hemostatic Sealants:

Gelatin-based hemostatic sealants are another important category within the market, known for their rapid hemostatic properties and ability to conform to tissue surfaces. These sealants are primarily composed of gelatin derived from animal sources, which is processed to produce a product that can absorb moisture and promote clotting. Their application spans a variety of surgical procedures, particularly in situations requiring quick control of bleeding, such as during liver surgeries and other vascular interventions. The growing adoption of gelatin-based sealants can be attributed to their effectiveness, relatively low cost compared to other options, and favorable safety profile, making them an appealing choice for both patients and healthcare providers.

Fibrin-based Hemostatic Sealants:

Fibrin-based hemostatic sealants are derived from human or animal fibrinogen and thrombin, mimicking the body's natural clotting mechanism. These sealants are particularly well-suited for surgeries involving large tissue defects, as they provide a strong adhesive property that aids in wound closure and healing. The ability of fibrin sealants to promote natural healing processes while simultaneously providing hemostatic effects makes them invaluable in complex surgical scenarios. As surgeons increasingly seek to reduce the risk of complications associated with traditional suturing techniques, the demand for fibrin-based sealants is expected to rise significantly, further solidifying their position in the hemostatic tissue sealants market.

Thrombin-based Hemostatic Sealants:

Thrombin-based hemostatic sealants are specifically designed to leverage the coagulation enzyme thrombin's properties to promote rapid clot formation. These sealants are often utilized in surgical procedures where immediate hemostatic control is required, such as in orthopedic and cardiac surgeries. The unique formulation of thrombin-based agents allows for quick action upon application, making them a critical tool for surgeons seeking to minimize blood loss. The ongoing research into enhancing the efficacy and safety of thrombin-based sealants is expected to drive innovation within this segment, broadening their application scope and increasing market penetration.

Synthetic Hemostatic Sealants:

Synthetic hemostatic sealants represent a newer segment within the market, characterized by their composition from synthetic materials designed to achieve rapid hemostasis. These products are increasingly being developed to address specific clinical needs, offering enhanced safety and efficacy profiles. The ability of synthetic agents to provide consistent performance without the risk of disease transmission associated with animal-derived products is a significant advantage. As the medical community becomes more aware of the benefits of synthetic options, their acceptance and usage in surgical settings are expected to increase, thereby contributing positively to market growth.

By Application

General Surgery:

In the realm of general surgery, hemostatic tissue sealants are extensively utilized to manage bleeding and promote healing. The high prevalence of surgical interventions in this domain and the necessity for effective hemostatic solutions create a significant demand for these products. General surgery encompasses various procedures, including appendectomies and cholecystectomies, where the risk of postoperative bleeding is a concern. The introduction of advanced hemostatic agents designed specifically for general surgical applications is expected to enhance patient safety and outcomes, driving market growth in this segment.

Cardiac Surgery:

Cardiac surgery necessitates the highest level of precision and effective hemostasis due to the critical nature of the procedures. Hemostatic tissue sealants play a vital role in controlling bleeding during and after surgeries such as coronary artery bypass grafting and valve replacements. Given the complexity of cardiac surgeries and the extensive vascular manipulation involved, the demand for reliable hemostatic solutions is paramount. As cardiac procedures become more sophisticated, the integration of innovative hemostatic sealants that ensure optimal performance will likely elevate their utilization and market presence within this specialty.

Vascular Surgery:

Vascular surgery involves intricate procedures that often lead to significant bleeding, making hemostatic sealants essential in this field. These sealants are employed to address bleeding during surgeries involving blood vessels, such as aneurysm repair or bypass grafting. Given the critical importance of maintaining blood flow and preventing complications, the use of hemostatic agents that provide rapid clotting and tissue adherence is increasingly favored. The ongoing advancements in vascular surgical techniques and technologies are anticipated to drive the demand for specialized hemostatic products, further solidifying their role in the vascular surgery market.

Orthopedic Surgery:

Orthopedic surgery encompasses a variety of procedures that frequently result in significant blood loss, particularly in trauma cases or joint replacement surgeries. Hemostatic tissue sealants are employed in orthopedic surgeries to effectively manage bleeding, reduce recovery times, and promote healing. The growing aging population and the rising incidence of orthopedic conditions, such as arthritis, are driving an increase in procedures in this specialty. As surgeons become more familiar with the benefits of hemostatic agents, their use in orthopedic applications will likely expand, contributing to overall market growth.

Neurosurgery:

Neurosurgery is another critical area where hemostatic tissue sealants are indispensable. Given the sensitivity and complexity of the nervous system, achieving optimal hemostasis is vital to minimize complications and enhance surgical outcomes. Hemostatic agents are used to control bleeding in procedures such as craniotomies and spinal surgeries. The increasing prevalence of neurological disorders necessitating surgical intervention is expected to boost the demand for effective hemostatic solutions within this segment. As the field of neurosurgery continues to evolve, the integration of advanced hemostatic agents will remain instrumental in improving patient care.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for hemostatic tissue sealants, as they provide comprehensive surgical services across multiple specialties. The majority of surgical procedures are performed in hospital settings, which necessitates a steady supply of hemostatic products to manage bleeding effectively. Hospitals prioritize the availability of innovative and reliable hemostatic options to ensure optimal patient outcomes. Additionally, the procurement strategies adopted by hospitals often favor established suppliers with a proven track record of product efficacy, further solidifying their role as the dominant channel for distributing hemostatic sealants.

Specialty Clinics:

Specialty clinics are emerging as significant distribution channels for hemostatic tissue sealants, catering to specific surgical specialties such as orthopedics or vascular surgery. These clinics often focus on providing targeted surgical interventions, leading to a tailored approach to hemostatic solutions that align with their procedures. The growing trend of outpatient surgeries and the shift toward specialized care are driving the demand for hemostatic products in these settings. Furthermore, specialty clinics prioritize the use of advanced technologies and innovative products to enhance patient care, making them a vital player in the distribution landscape.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have gained traction as an essential distribution channel for hemostatic tissue sealants, particularly for outpatient procedures. The increasing preference for minimally invasive surgeries performed in ASCs is a significant factor driving the demand for effective hemostatic solutions. ASCs aim to provide high-quality care while minimizing patient recovery times, making the integration of hemostatic agents crucial for achieving successful outcomes. The regulatory environment for ASCs continues to evolve, further expanding their capabilities and facilitating the adoption of advanced hemostatic products.

Online Sales:

The rise of e-commerce has transformed the distribution landscape for hemostatic tissue sealants, with online sales channels providing convenient access to a wide array of products. Healthcare providers increasingly utilize online platforms to procure hemostatic agents, particularly in light of the ongoing digital transformation in the healthcare sector. Online sales channels offer benefits such as competitive pricing, ease of ordering, and rapid delivery, facilitating timely access to essential surgical products. As healthcare systems continue to embrace digital solutions, the role of online sales in the hemostatic tissue sealants market is expected to grow substantially.

By Ingredient Type

Absorbable:

Absorbable hemostatic tissue sealants are designed to offer temporary control of bleeding while naturally being absorbed by the body over time. This category of sealants is particularly beneficial in surgical settings where long-term stability is not required. The growing preference for absorbable agents is largely attributed to their ability to minimize the risk of foreign body reactions and reduce the need for additional surgical interventions for product removal. As the medical community increasingly recognizes the benefits of absorbable products, their demand within the market is expected to rise significantly.

Non-absorbable:

Non-absorbable hemostatic tissue sealants provide a permanent solution for managing bleeding during surgical procedures. These products are often utilized in situations where long-lasting hemostatic control is necessary, such as in complex surgeries. The advantages of non-absorbable sealants include their strength and reliability, particularly in high-stress areas of the body. As surgical techniques advance and the complexity of procedures increases, the demand for non-absorbable hemostatic agents is anticipated to grow, positioning them as a key component of the hemostatic tissue sealants market.

Combination:

Combination hemostatic tissue sealants leverage the benefits of both absorbable and non-absorbable agents, offering surgeons greater flexibility in managing bleeding. These products are designed to provide immediate hemostatic control through absorbable components while ensuring long-term stability through non-absorbable elements. The innovative design of combination sealants addresses the diverse needs of surgical procedures, making them increasingly popular among healthcare providers. As surgical practices evolve and the need for versatile hemostatic solutions grows, the combination segment is expected to gain a significant share in the market.

By Region

North America is expected to dominate the global hemostatic tissue sealants market, accounting for approximately 40% of the total market share by 2035. The region's advanced healthcare infrastructure, coupled with a high volume of surgical procedures and robust adoption of innovative medical technologies, significantly contributes to this leading position. Furthermore, the increasing prevalence of chronic diseases leading to surgical interventions, along with extensive research and development activities in the medical field, are poised to drive market growth in North America. With an anticipated CAGR of 7.5% during the forecast period, the market in this region is expected to witness significant advancements in the development and adoption of hemostatic products.

Europe is also expected to contribute substantially to the hemostatic tissue sealants market, projected to account for about 30% of the total market share by 2035. The region benefits from a well-established healthcare system that emphasizes patient safety and the continuous improvement of surgical outcomes. The rising incidence of surgical procedures, along with increased investments in healthcare infrastructure, is responsible for the growth forecast in Europe. Additionally, the growing collaboration between manufacturers and healthcare providers to enhance the availability and effectiveness of hemostatic solutions will further reinforce the market position in this region. The compound annual growth rate (CAGR) for Europe is estimated to be around 6.2% during the forecast period, reflecting the region’s commitment to advancing medical technologies.

Opportunities

One of the primary opportunities in the hemostatic tissue sealants market is the increasing demand for advanced surgical techniques, particularly minimally invasive surgeries. As surgical technologies evolve, there is a growing need for products that can effectively manage bleeding without compromising patient safety and recovery times. Hemostatic tissue sealants that are designed specifically for minimally invasive procedures can capitalize on this trend by offering surgeons reliable and efficient solutions. Additionally, the expanding application of hemostatic agents in emerging markets presents a significant opportunity for growth, as healthcare systems in these regions continue to develop and modernize. The potential for product innovation and the introduction of novel formulations tailored to meet the distinct requirements of various surgical specialties can drive market expansion and enhance competitiveness.

Another compelling opportunity lies in the increasing focus on patient-centric healthcare solutions, where the emphasis is on improving surgical outcomes and enhancing the overall patient experience. As healthcare providers prioritize safety and efficiency, the adoption of hemostatic tissue sealants that minimize complications and promote faster recovery becomes imperative. Furthermore, collaborative efforts between manufacturers and healthcare institutions can pave the way for developing tailored hemostatic solutions that address specific clinical challenges. By leveraging technological advancements and engaging in strategic partnerships, companies can position themselves effectively in the market, driving innovation and meeting the evolving needs of healthcare professionals and patients alike.

Threats

The hemostatic tissue sealants market faces several threats that could impede its growth trajectory. One of the most significant threats is the stringent regulatory landscape governing medical devices, which can lead to delays in product approvals and increased costs for manufacturers. Compliance with these regulations is essential to ensure product safety and efficacy, but it can also limit the speed at which new products are introduced to the market. Furthermore, the presence of a wide array of competing products, particularly from established players with extensive market reach, poses a challenge for new entrants seeking to carve out a share of the market. In this highly competitive environment, companies must continuously innovate and differentiate their products to remain relevant.

Moreover, the market is subject to the risks associated with supply chain disruptions, particularly in the context of global events that can affect production and distribution. The reliance on specific ingredients or materials for hemostatic sealants can lead to vulnerabilities if there are shortages or trade restrictions. Additionally, the growing trend towards cost containment in healthcare may pressure manufacturers to reduce prices, potentially impacting profit margins. As healthcare providers seek to balance the costs of surgical procedures while ensuring high-quality care, the hemostatic tissue sealants market must navigate these challenges to maintain growth and sustainability.

Competitor Outlook

• Johnson & Johnson
• Baxter International Inc.
• Medtronic
• Boston Scientific Corporation
• Ethicon, Inc. (a subsidiary of Johnson & Johnson)
• 3M Company
• Integra LifeSciences Corporation
• Coloplast A/S
• Hemostasis, LLC
• Biolife Plasma Services
• Surgeon’s Choice, LLC
• Adhesives Research, Inc.
• FzioMed Inc.
• W.L. Gore & Associates, Inc.
• Advanced Medical Solutions Group plc

The competitive landscape of the hemostatic tissue sealants market is characterized by the presence of both established industry players and emerging companies that are vying for market share through innovation and strategic partnerships. The leading companies, such as Johnson & Johnson and Baxter International, have leveraged their strong brand presence and extensive distribution networks to maintain dominance in this market. These organizations invest heavily in research and development to ensure a steady pipeline of new products that meet the evolving needs of healthcare professionals. Moreover, collaborations with academic institutions and healthcare providers allow them to stay ahead of the competition by gaining insights into market trends and clinical requirements.

Medtronic is another major competitor in the hemostatic tissue sealants market, known for its comprehensive portfolio that includes various hemostatic products tailored for different surgical applications. The company’s focus on innovation and commitment to improving patient outcomes have cemented its position as a leader in the industry. Additionally, Boston Scientific Corporation and Ethicon, Inc. have made significant strides in this space, with a strong emphasis on developing advanced hemostatic solutions that are both effective and safe for patient use. These companies continuously explore partnerships and acquisitions as a strategy to enhance their product offerings and expand their market reach.

Emerging players such as FzioMed Inc. and Advanced Medical Solutions Group plc are also making considerable contributions to the hemostatic tissue sealants market. These companies are focused on developing unique formulations and innovative delivery systems that set their products apart from traditional options. By addressing specific clinical challenges and tailoring solutions to meet the needs of surgeons and patients, they are carving out a niche in the competitive landscape. Overall, the hemostatic tissue sealants market is witnessing a dynamic competitive environment, with companies striving to innovate and enhance the effectiveness of their products to drive market growth.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 3M Company
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 FzioMed Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Coloplast A/S
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Hemostasis, LLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Biolife Plasma Services
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Adhesives Research, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Baxter International Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 W.L. Gore & Associates, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boston Scientific Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Integra LifeSciences Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Surgeon’s Choice, LLC
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Advanced Medical Solutions Group plc
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Ethicon, Inc. (a subsidiary of Johnson & Johnson)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hemostatic Tissue Sealants Market, By Application
    • 6.1.1 General Surgery
    • 6.1.2 Cardiac Surgery
    • 6.1.3 Vascular Surgery
    • 6.1.4 Orthopedic Surgery
    • 6.1.5 Neurosurgery
  • 6.2 Hemostatic Tissue Sealants Market, By Product Type
    • 6.2.1 Collagen-based Hemostatic Sealants
    • 6.2.2 Gelatin-based Hemostatic Sealants
    • 6.2.3 Fibrin-based Hemostatic Sealants
    • 6.2.4 Thrombin-based Hemostatic Sealants
    • 6.2.5 Synthetic Hemostatic Sealants
  • 6.3 Hemostatic Tissue Sealants Market, By Ingredient Type
    • 6.3.1 Absorbable
    • 6.3.2 Non-absorbable
    • 6.3.3 Combination
  • 6.4 Hemostatic Tissue Sealants Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Hemostatic Tissue Sealants Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hemostatic Tissue Sealants market is categorized based on

By Product Type

• Collagen-based Hemostatic Sealants
• Gelatin-based Hemostatic Sealants
• Fibrin-based Hemostatic Sealants
• Thrombin-based Hemostatic Sealants
• Synthetic Hemostatic Sealants

By Application

• General Surgery
• Cardiac Surgery
• Vascular Surgery
• Orthopedic Surgery
• Neurosurgery

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Online Sales

By Ingredient Type

• Absorbable
• Non-absorbable
• Combination

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Baxter International Inc.
• Medtronic
• Boston Scientific Corporation
• Ethicon, Inc. (a subsidiary of Johnson & Johnson)
• 3M Company
• Integra LifeSciences Corporation
• Coloplast A/S
• Hemostasis, LLC
• Biolife Plasma Services
• Surgeon’s Choice, LLC
• Adhesives Research, Inc.
• FzioMed Inc.
• W.L. Gore & Associates, Inc.
• Advanced Medical Solutions Group plc